Gastric release pulse system for drug delivery
View Patent ↗Disclosed are pharmaceutical products for providing pulses of at least one pharmaceutically active ingredient from a patient's stomach, or from a subsequent gastrointestinal site proximal thereto, for absorption thereof at a site(s) more distal in the gastrointestinal tract than the patient's stomach, or than the subsequent gastrointestinal site proximal thereto. The product comprises first, second, and third pharmaceutical dosage forms, each of which comprises at least one pharmaceutically active agent and a pharmaceutically acceptable carrier. The product is formulated such that at least two of the first, second, and third pharmaceutical dosage forms further comprise means for providing temporary gastric-retention of the at least two of the first, second, and third pharmaceutical dosage forms within the patient's stomach, or at the subsequent gastrointestinal site proximal thereto.
1. An oral pharmaceutical product for providing at least three pulses of at least one antibiotic to a patient, said at least three pulses being released from said product from a first location in the patient's gastrointestinal tract, wherein said first location in the patient's gastrointestinal tract is the stomach, for absorption thereof at a second location in the patient's gastrointestinal tract, said second location being different from said first location and being more distal in the gastrointestinal tract than said first location, said second location in the patient's gastrointestinal tract being selected from the group consisting of the duodenum, the jejunum, the ileum, the colon, and combinations of the foregoing, said product comprising:
first, second, and third pharmaceutical dosage forms; each of said pharmaceutical dosage forms comprising at least one antibiotic and a pharmaceutically acceptable carrier, wherein the at least second pharmaceutical dosage form comprises at least one of a bioadhesive coating, a high density material, a floating material or a diameter of 7 mm or greater,
wherein the at least third pharmaceutical dosage form comprises at least one of a bioadhesive coating, a high density material, a floating material or a diameter of 7 mm or greater;
wherein said 7 mm diameter, said bioadhesive coating, said high density material and/or said floating material provide temporary gastric retention within said first location in the patient's gastrointestinal tract via size exclusion, bioadhesion or density manipulation;
wherein each of said first, second, and third pharmaceutical dosage forms have different lag times,
wherein the first pharmaceutical dosage form is an immediate release dosage form, the second pharmaceutical dosage form is a delayed release dosage form comprising a pH-independent release mechanism, and wherein said delayed release dosage form exhibits a lag time followed by rapid release of the at least one antibiotic, wherein the third dosage form is a sustained release dosage form, and
wherein the at least one antibiotic of said third dosage form is released after the at least one antibiotic of the second dosage form and wherein 100% of the at least one antibiotic of the second dosage form is released within one hour of initiation of release.
2. The pharmaceutical product of claim 1 , wherein the oral product is selected form the group consisting of tablets, capsules, sachets, sprinkles, ampules, solutions, and multiple units thereof.
3. The pharmaceutical product of claim 1 , wherein the release of said pulse of at least one antibiotic from each of said pharmaceutical dosage forms is separated by at least one hour.
4. The pharmaceutical product of claim 1 , wherein said pulse of at least one antibiotic from each of said pharmaceutical dosage forms is about at least 50% dissolved before release of said pulse of at least one antibiotic is initiated from the subsequently releasing dosage form.
5. The pharmaceutical product of claim 1 , wherein the release of said pulse of at least one antibiotic from each of said pharmaceutical dosage forms is separated by about at least one hour and wherein said pulse of at least one antibiotic from each of said pharmaceutical dosage forms is about at least 50% dissolved before release of said pulse of at least one antibiotic is initiated from the subsequently releasing dosage form.
6. The pharmaceutical product of claim 1 , wherein the pulses are released so that the corresponding C max of each of the at least three pulses is distinguishable in a pharmacokinetic plasma profile.
7. The pharmaceutical product of claim 1 , wherein the pulses are released so that the corresponding T max of each of the at least three pulses is distinguishable in a pharmacokinetic plasma profile.
8. The pharmaceutical product of claim 1 , wherein the corresponding C max and T max of each of the at least three pulses is distinguishable in a pharmacokinetic plasma profile.
9. The pharmaceutical product of claim 1 , wherein the antibiotic is selected from metronidazole, cephalexin and amoxicillin.